u/oaksapollo · 38d ago1 prior · awaiting results
7 reasons why investors dismiss Lucid Diagnostics LUCD (from least valid to most)
Lucid Diagnostics' EsoGuard test addresses early detection of Barrett's esophagus, a precancerous condition where competing multi-cancer blood tests fail (sensitivity <12.5%). With a $60B TAM based on 30M screening population and $1938 CMS price, capturing just 1% annually yields $581M revenue, while the company currently tests 3-4K per quarter and breaks even at 5-6K—offering significant upside from a $150M market cap despite valid concerns around dilution and management guidance errors.